SemaxСемакс
What is it?
A synthetic peptide based on a fragment of adrenocorticotropic hormone (ACTH). Its research focuses on brain function and responses to neurological injury.
Identity / background source ↗
Research context
A 1997 comparative clinical report investigated Semax alongside conventional treatment in acute ischemic stroke. This is not a study of healthy-person cognitive enhancement.
- Working classification
- Peptide
- Research collection
- Neuropeptide research · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —Clinical comparison
- Study methods
- —Abstract-level review
- Independent replication
- —Not assessed
- Source access
- —English abstract
- Safety evidence
- —Not assessed
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Linked sources
Explore the research map and unresolved leads ↗
Neuroprotective effects of peptides bioregulators in people of various age
R. S. Umnov, N. S. Linkova, V. Kh. Khavinson · Adv Gerontol. 26(4):671–678. PMID 24738258
A gateway review comparing polypeptide complexes (Cortexin and Cerebrolysin) with short peptides (Semax, Cortagen and Pinealon). It discusses older populations and cellular mechanisms; the abstract supplies no trial-quality assessment.
- Population / setting
- Review of earlier research
- What was checked
- Indexed English abstract checked; Russian full text not retrieved.
Limitations & review scope
- Source-linked does not mean a completed risk-of-bias review.
- A review is not an independent clinical replication; proposed mechanisms do not establish efficacy or safety.
Source checked 2026-09-27. This is a source-linked record, not a completed evidence review.
Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)
E. I. Gusev, V. I. Skvortsova, N. F. Miasoedov, V. N. Nezavibatko, E. Iu. Zhuravleva, A. V. Vanichkin · Zh Nevrol Psikhiatr Im S S Korsakova. 97(6):26–34
The report studied Semax alongside intensive stroke care and described neurological and electrophysiological changes.
- Population / setting
- 30 Semax-treated patients; 80 conventional-treatment controls
- What was checked
- PubMed record and English abstract checked.
Limitations & review scope
- The abstract does not establish random allocation or blinding.
- Disease-specific adjunctive care does not demonstrate healthy-person cognitive enhancement.
- Full results, adverse-event reporting, and independent replication require review.
Source checked 2026-09-27. This is a source-linked record, not a completed evidence review.